Address
3300 Bee Cave Road
Austin, TX 78746
United States of America (the)
Phone
877 774 4679
Website
Sector
Healthcare
Industry
Biotechnology
Employees
15
First IPO Date
March 29, 2018
| Name | Title | Pay | Year Born |
| Ryan Confer | President, Chief Executive Officer, Chief Financial Officer & Director | 638,421 | 1982 |
| Mark S. Berger | Chief Medical Officer | 631,319 | 1955 |
| Greg Jancarik | Senior Director & Corporate Controller | 0 | N/A |
| Celina Laney | Chief of Staff | 0 | N/A |
| Jack A. Roth | Chairman of Scientific & Medical Advisory Board | 0 | N/A |
| David Schloss | Senior Vice President of Human Resources | 0 | N/A |
| Thomas C. Gallagher | Senior Vice President of Intellectual Property & Licensing | 0 | N/A |
| Suzanne Thornton-Jones | Senior Vice President of Regulatory Affairs & Quality | 0 | N/A |
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.